H.C. Wainwright reiterated its Buy rating for Tscan Therapeutics on August 13, 2026. The firm issued this update one day after Tscan released its second-quarter financial results.
The August 12 report presented a mixed financial outcome. Earnings per share beat analyst estimates. Revenue fell short of expectations.
Filings revealed substantial doubt about the company's ability to continue as a going concern over the next year. Tscan stated its current cash reserves will only fund operations into the second quarter of 2027.
Additionally, principal payments on an outstanding loan are scheduled to accelerate. This disclosure highlights critical financial instability for the clinical-stage biotechnology firm.